Summary
Quest Diagnostics reported its first-quarter 2023 financial results, showing a decrease in net revenues and net income compared to the prior year. This decline was primarily driven by a significant reduction in COVID-19 testing volumes, which had a substantial impact on overall revenue and profitability. Despite the top-line decrease, the company highlighted growth in its "base business" revenue, excluding COVID-19 testing, indicating resilience in its core operations. The company also provided an update on its strategic initiatives, including the "Invigorate" program aimed at cost structure improvement. Management discussed ongoing investments in acquisitions, such as the recent purchase of New York-Presbyterian's laboratory assets and the planned acquisition of Haystack Oncology, signaling a continued focus on strategic growth and expanding service offerings in specialized areas like oncology. Investors should monitor the integration of these acquisitions and the continued growth of the base business as key indicators of future performance.
Financial Highlights
57 data points| Revenue | $2.33B |
| Cost of Revenue | $1.56B |
| Gross Profit | $771.00M |
| SG&A Expenses | $439.00M |
| Operating Expenses | $2.03B |
| Operating Income | $305.00M |
| Interest Expense | $37.00M |
| Net Income | $202.00M |
| EPS (Basic) | $1.80 |
| EPS (Diluted) | $1.78 |
| Shares Outstanding (Basic) | 112.00M |
| Shares Outstanding (Diluted) | 113.00M |
Key Highlights
- 1Net revenues decreased by 10.7% to $2.331 billion in Q1 2023 compared to $2.611 billion in Q1 2022.
- 2Net income attributable to Quest Diagnostics decreased significantly by 43.0% to $202 million in Q1 2023 from $355 million in Q1 2022.
- 3Diluted earnings per share (EPS) fell to $1.78 in Q1 2023, down from $2.92 in Q1 2022.
- 4The decline in revenue was largely attributed to a substantial decrease in COVID-19 testing revenue, which fell to $119 million from $599 million year-over-year.
- 5The "base business" revenue (excluding COVID-19 testing) grew by 10.3% year-over-year, with base testing volume increasing by 7.9%.
- 6The company repurchased no shares of its common stock in Q1 2023, compared to $350 million in Q1 2022, though it increased its share repurchase program authorization by $1 billion in February 2023.
- 7Quest Diagnostics completed the acquisition of select assets of New York-Presbyterian's laboratory services business in April 2023 for $275 million and announced an agreement to acquire Haystack Oncology, Inc. for approximately $300 million plus potential future milestones.